Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea

PURPOSE: M1 macrophages can promote corneal allograft rejection (CGR). Inhibiting M1 macrophage polarization by the JAK/STAT1 pathway may be a new strategy to prevent CGR. Tofacitinib, a potent pan-JAK inhibitor, can inhibit JAK/STAT activation. Here, we investigated the inhibitory effects of tofaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jianfeng, Li, Pengfei, Li, Zhuang, Li, Yingqi, Luo, Jiawei, Su, Wenru, Liang, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976928/
https://www.ncbi.nlm.nih.gov/pubmed/35353151
http://dx.doi.org/10.1167/tvst.11.3.34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976928/
https://www.ncbi.nlm.nih.gov/pubmed/35353151
http://dx.doi.org/10.1167/tvst.11.3.34

Ejemplares similares